Supplementary Material

Inclusion and Exclusion Criteria	pg 2
Figure S1: Phase 1 Study Design	pg 5
Table S1: Phase 1 Patient Demographics and Baseline Characteristics	pg 6
Table S2: Phase 2 Variant Lineages at Baseline	pg 7
Table S3: Bebtelovimab Population Pharmacokinetic Model Parameters	pg 8
Table S4: Model-Estimated Reduction in Viral Load Following a Single IV Dose of 175 mg Bebtelovimab Relative to Placebo Depending on the Time of Treatment	pg 9
Figure S2: Model-Estimated Typical Viral Load Profiles Showing Impact of Infection with the Delta Variant.	pg 10
Figure S3: Model-Estimated Typical Viral Load Profiles Showing Impact of Age on Viral Dynamics.	pg 11
Table S5: Phase 1: Overview of Adverse Events following IV Infusion	pg 12

Inclusion and Exclusion Criteria

Inclusion Criteria	Exclusion Criteria
 Age ≥18 and <65 years of age at the time of randomization 	 Medical Conditions BMI ≥35 SpO2 ≤93% on room air at sea level or PaO2/FiO2 <300, respiratory rate ≥30 per minute, heart rate ≥125 per minute Require mechanical ventilation or anticipated impending need for mechanical ventilation
 Disease Characteristics Do not have a risk factor defined for High-risk population (for placebo- controlled Low-risk population only) Currently not hospitalized Have one or more mild or moderate COVID-19 symptoms Fever Cough Sore throat Malaise Headache Muscle pain Gastrointestinal symptoms, or Shortness of breath with exertion Nasal congestion or runny nose New loss of smell Chills Must have sample collection for first positive SARS-CoV-2 viral infection determination ≤3 days prior to start of the infusion 	 Other Exclusions History of a positive SARS-CoV-2 serology test History of a positive SARS-CoV-2 test prior to the 1 serving as eligibility for this study Received any treatment, vaccine, or intervention for SARS-CoV-2

Phase 1 substudy and placebo-controlled Low-risk population

Abbreviations: BMI = body mass index; COVID-19 = coronavirus disease 2019; FiO2 = fraction of inspired oxygen in the air; PaO2 = partial pressure of oxygen; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SpO2 = saturation of peripheral oxygen.


Open-label, High-Risk population

Inclusion Criteria	Exclusion Criteria
Age and Risk Factors	Medical Conditions
 ≥18 years of age and have at least 1 of the following risk factors Are ≥65 years of age Have a BMI ≥35 Have chronic kidney disease Have type 1 or type 2 diabetes Have immunosuppressive disease Are currently receiving immunosuppressive treatment, or Are ≥55 years of age AND have cardiovascular disease, OR hypertension, OR chronic obstructive pulmonary disease or other chronic respiratory disease 12 to 17 years of age and have at least 1 of the following risk factors Have a BMI ≥85th percentile for their age and gender based on CDC growth charts Have congenital or acquired heart disease Have neurodevelopmental disorders, Have a medical-related technological dependence Have asthma or reactive airway or other chronic respiratory disease that requires daily medication for control Have type 1 or type 2 diabetes Have chronic kidney disease 	 SpO2 ≤93% on room air at sea level o PaO2/FiO2 <300, respiratory rate ≥30 per minute, heart rate ≥125 per minute Require mechanical ventilation or anticipated impending need for mechanical ventilation

Ago and Dick Fosters (arrelled	
Age and Risk Factors (enrolled according to	
updated CDC criteria)	
• ≥12 years of age and have at least 1 of	
the following risk factors	
 Are ≥65 years of age 	
 Are adults (≥18 years of age) 	
with BMI >25 kg/m2, or if age	
12-17, have BMI ≥85th	
percentile for their age and	
gender based on CDC growth	
charts	
• Have chronic kidney disease	
 Have type 1 or type 2 diabetes Have immunosuppressive 	
 Have immunosuppressive disease 	
 Are currently receiving 	
immunosuppressive treatment	
 Have cardiovascular disease 	
(including congenital heart	
disease) or hypertension	
 Have chronic lung diseases 	
 Have sickle cell disease 	
 Have a neurodevelopmental 	
disorder or other conditions that	
confer medical complexity, or	
• Have a medical-related	
technological dependence	
Disease Characteristics	Other Exclusions
Currently not hospitalized	 History of a positive SARS-CoV-2
Have one or more mild or moderate	serology test
COVID-19 symptoms	 History of a positive SARS-CoV-2 test
○ Fever	prior to the 1 serving as eligibility for
○ Cough	this study
 Sore throat 	Received any treatment or
 Malaise 	investigational intervention for SARS-
 Headache 	CoV-2 (not including SARS-CoV-2 vaccine)
• Muscle pain	vaccine)
 Gastrointestinal 	
symptoms, or	
 Shortness of breath with 	
exertion	
 Nasal congestion or 	
runny nose	
• New loss of smell	
• Chills	
 Must have sample collection for first positive SABS_CoV_2 viral infection 	
positive SARS-CoV-2 viral infection	

determination ≤3 days prior to start of the infusion		

Abbreviations: BMI = body mass index; COVID-19 = coronavirus disease 2019; FiO2 = fraction of inspired oxygen in the air; PaO2 = partial pressure of oxygen; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SpO2 = saturation of peripheral oxygen.



Note: First 2 participants were sentinel in each dose cohort (Active Treatment: Placebo)

Figure S1: Phase 1 Study Design. Abbreviations: BAM = bamlanivimab; BEB = bebtelovimab; ETE = etesevimab; hr = hour; mg = milligrams; min = minutes; n = number of participants. **Note:** The first 2 participants in each cohort were sentinel (BEB:placebo). Subsequent participants were randomized to the remaining treatment allocations, 5 to BEB or BEB+BAM+ETE, and 1 to placebo.

Table S1: BLAZE-4 Phase I: Demographics and Baseline Characteristics of Ambulatory Patients with

 COVID-19 Administered mAb Treatment via Intravenous Infusion

	РВО	BEB	BEB	BEB	BEB+BAM	BEB	Total
Dose		70 mg	175 mg	175 mg	+ETE 175+700+ 1400 mg	1750 mg	
Rate		140 mg / min	140 mg / min	350 mg / min	350 mg / min	350 mg / min	
Total (N)	N=10	N=6	N=6	N=6	N=6	N=6	N=40
Female, n (%)	3 (30)	3 (50)	6 (100)	1 (17)	3 (50)	5 (83)	21 (53)
Age, (median)	51.0	33.5	50.0	29.5	41.5	37.5	41.5
Race or ethnic gro	u p, n (%)						
Black or African American	1 (10)	0	0	0	0	0	1 (3)
Hispanic or Latino	3 (30)	0	0	1 (17)	1 (17)	2 (33)	7 (18)
White	9 (90)	6 (100)	6 (100)	6 (100)	6 (100)	6 (100)	39 (98)
BMI, (mean (SD))	30.7 (7.0)	28.1 (2.3)	25.8 (4.6)	26.7 (5.3)	26.4 (5.0)	25.5 (5.3)	27.6 (5.4)
SpO ₂ Category, n (%)						
<96%	2 (20)	0	0	0	1 (17)	1 (17)	4 (10)
≥96%	8 (80)	6 (100)	6 (100)	6 (100)	5 (83)	5 (83)	36 (90)
COVID-19 Disease	Status , n (%)					
Mild	10 (100)	5 (83)	5 (83)	6 (100)	4 (67)	5 (83)	35 (88)
Moderate	0	1 (17)	1 (17)	0	2 (33)	1 (17)	5 (13)
Duration of symptom onset to randomization, Median (range)	3.0 (0-5)	2.0 (1–4)	3.5 (0-7)	3.5 (3-7)	3.5 (2-7)	4.0 (2-5)	3.0 (0-7)
Baseline viral load, mean	6.9	7.3	5.9	6.9	6.7	6.3	6.7
Seropositive at baseline, n (%)	2 (22)	1 (17)	0	0	1 (17)	1 (17)	5 (14)

Abbreviations: BAM, bamlanivimab; BEB, bebtelovimab; BMI, body mass index (kg m²); COVID-19 = coronavirus disease 2019; ETE, etesevimab; kg, kilograms; m, meters; mAb, monoclonal antibody;

mg, milligrams; min, minutes; N, number of patients in the analysis population; n, number of patients in the specified category; PBO, pooled placebo; SD, standard deviation; SpO₂, oxygen saturation

	Placebo	BEB	BEB+BAM+ETE	Total
Alpha	23.1% (25/108)	41.8% (84/201)	21.9% (66/302)	28.6% (175/611)
Beta	0 (0/108)	0.5% (1/201)	0.7% (2/302)	0.5% (3/611)
Gamma	6.5% (7/108)	5.0% (10/201)	5.6% (17/302)	5.6% (34/611)
Delta	60.2% (65/108)	31.3% (63/201)	58.3% (176/302)	49.8% (304/611)
Delta + K417N	0 (0/108)	0.5% (1/201)	1.3% (4/302)	0.8% (5/611)
lota	0.9% (1/108)	1.5% (3/201)	0 (0/302)	0.7% (4/611)
Lambda	0 (0/108)	0.5% (1/201)	0.7% (2/302)	0.5% (3/611)
Mu	2.8% (3/108)	5.0% (10/201)	3.3% (10/302)	3.8% (23/611)
Non-WHO classified	1.9% (2/108)	4.5% (9/201)	2.3% (7/302)	2.9% (18/611)
Not determined	4.6% (5/108)	9.5% (19/201)	6.0% (18/302)	6.9% (42/611)

Table S2. Variant Lineages at Baseline_BLAZE-4 Phase 2 Low and High-Risk Patient Cohorts.

Abbreviations: BAM = bamlanivimab; BEB = bebtelovimab; ETE = etesevimab; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; WHO = World Health Organization.

Parameter Description	Population Estimate	%SEE	Interindividual Variability	%SEE
CL (L/d)	0.29	1.452	33.4	5.92
Q (L/d)	0.248	1.847		
Effect ^a of body weight on CL and Q	0.81	(Fixed)		
V1 (L)	2.45	1.424	30.5	7.25
V2 (L)	1.37	1.453		
Effect ^b of body weight on V1 and	1	(Fixed)		
Residual Error (proportional)	0.188	2.037	87.1	7.22

Table S3: Bebtelovimab Population Pharmacokinetic Model Parameters

Abbreviations: CL = systemic clearance; Q = intercompartmental clearance; SEE = standard error of the estimate; V1 = central compartment volume of distribution; V2 = peripheral volume of distribution.

^aParameter = Population Estimate × (body weight/70)^{0.81}. (Exponent from [Betts et al. 2018¹])

^bParameter = Population Estimate × (body weight/70).

Table S4: Model-Estimated Reduction in Viral Load Following a Single IV Dose of 175 mg BebtelovimabRelative to Placebo Depending on the Time of Treatment

Bebtelovimab administration relative to symptoms onset (Days)	Reduction in time-weighted average log ₁₀ viral load from Days 0 to 7 relative to placebo (% absolute decrease)ª
1 (Delta positive)	0.93 (88.3%)
1 (Delta negative)	0.87 (86.5%)
4 (Delta positive)	0.80 (84.2%)
4 (Delta negative)	0.55 (71.8%)
10 (Delta positive)	0.31 (51.0%)
10 (Delta negative)	0.09 (18.7%)

Abbreviations: IV = intravenous; mg = milligrams.

^a % absolute reduction is calculated from the log₁₀ values according to the equation below:

 $P = (1 - 10^{-L}) \times 100$, where P is the percent absolute decrease, and L is the log₁₀ reduction.




Figure S2: Model-estimated typical viral load profiles showing impact of infection with the Delta variant. Change in viral load from baseline. Abbreviation: LY = 175 mg bebtelovimab.




Figure S3: Model-estimated typical viral load profiles showing impact of age on viral dynamics.

	Pooled Placebo N = 10	70 mg (BEB) N = 6	175 mg (BEB) N = 6	175 mg (BEB) N = 6	700 mg (BAM) + 1400 mg (ETE) + 175 mg (BEB) N = 6	1750 mg (BEB) N = 6	Total N = 40
		Dose 1 140 mg/min	Dose 2a 140 mg/min	Dose 2b 350 mg/min	Dose 2c 350 mg/min	Dose 3 350 mg/min	
Participants with ³ 1 TEAE n (%)	1 (10.0)	0	2 (33.3)	0	1 (16.7)	1 (16.7)	5 (12.5)
TEAE by severity ^a n (%)							
Mild Moderate Severe	1 (10.0) 0 0	0 0 0	2 (33.3) 0 0	0 0 0	1 (16.7) 0 0	1 (16.7) 0 0	5 (12.5) 0 0
Deaths n (%)	0	0	0	0	0	0	0
SAEs n (%)	0	0	0	0	0	0	0
Discontinuation from study treatment due to AEs n (%)	0	0	0	0	0	0	0

Table S5: BLAZE-4 Phase 1: Overview of Adverse Events following IV infusion

Abbreviations: BAM = bamlanivimab; ETE = etesevimab; BEB = bebtelovimab; mg = miligrams; min = minutes; AE = adverse event.; N = number of subjects in the analysis population; n = number of subjects in the specified category; SAE = serious adverse event; TEAE = treatment-emergent adverse event.

^aPatients with multiple occurrences of the same event are counted under the highest severity. Note: Patients with multiple occurrences of these categories are counted once for each category. Patients may be counted in more than one category. Deaths are also included as serious adverse events and discontinuations due to adverse events.

References

1. Betts A, Keunecke A, van Steeg TJ, et al. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. mAbs 2018;10:751-64.